It may not be surprising that Shanghai Junshi Biosciences has pushed back some clinical trials to prioritize its Eli Lilly-partnered Covid-19 antibody. But what exactly was sucking up their time is almost certain to raise some eyebrows: The company spent months finding enough monkeys on which to test the experimental drug.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,